To estimate the serum LDH levels in patients diagnosed of breast carcinoma
Author(s): Dr. Anshul Batalia and Dr. Shilpa Patankar
Abstract:Background & Method: This study was carried out over a period of Two Years (August 2014 to August 2016). The study was included 30 female age matched controls which do not have any other breast diseases and 30 female study subjects who had cytopathologically proven BREAST CANCER.
Result: In Study group, out of a total of 30 patients, 15 were found to have abnormal (> 460 IU/ L) levels of serum LDH. By using Chi-square test p-value < 0.05 therefore there is association between LDH level with group 1 and group 2.
Conclusion: The study had shown significant statistical difference in study group and control group which validates serum Lactate dehydrogenase as diagnostic marker. It is also observed that the values of Lactate dehydrogenase decreases with the due course of treatment, which can judge the response of disease to treatment especially in NACT protocol.
Dr. Anshul Batalia, Dr. Shilpa Patankar. To estimate the serum LDH levels in patients diagnosed of breast carcinoma. Int J Surg Sci 2021;5(2):272-274. DOI: https://doi.org/10.33545/surgery.2021.v5.i2e.707
